Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-991P is a **pseudogene** associated with the U6 small nuclear RNA gene family[1]. U6 snRNA itself is a critical component of the spliceosome, the molecular complex responsible for removing introns from pre-mRNA during splicing in the nucleus of eukaryotes[3][5]. Pseudogenes such as RNU6-991P typically arise from gene duplication or retrotransposition events and lack functional coding potential; most are nonfunctional and not expressed as active RNAs or proteins[4]. Some pseudogenes have been reported to play regulatory roles at the RNA level, influencing gene expression in certain contexts or in disease, most notably cancer, but such functions are identified only for a minority of pseudogenes and not for RNU6-991P specifically[4]. Therefore, RNU6-991P is not recognized as a therapeutic target, biomarker, or disease-associated gene, and is not a member of canonical receptor, enzyme, or similar molecular target families.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 991, pseudogene (RNU6-991P).